belantamab mafodotin + carfilzomib + pomalidomide + dexamethasone

This combination therapy consists of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone. It is currently being evaluated in a Phase II clinical trial led by the University of Chicago for the treatment of relapsed or refractory multiple myeloma, including patients who have previously received chimeric antigen receptor (CAR) T-cell therapy. Belantamab mafodotin is a first-in-class antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA), which delivers the cytotoxic microtubule inhibitor monomethyl auristatin F (MMAF) directly to plasma cells. Carfilzomib is a second-generation selective proteasome inhibitor that irreversibly binds to the 20S proteasome. Pomalidomide is a third-generation immunomodulatory imide drug (IMiD) that binds to cereblon, leading to the degradation of transcription factors Ikaros and Aiolos. Dexamethasone is a potent glucocorticoid that provides synergistic anti-inflammatory and pro-apoptotic effects. This multi-agent regimen aims to overcome treatment resistance through complementary mechanisms of action.

Other names

Belantamab Mafodotin + KPdBlenrep + KPdBelantamab Mafodotin + Carfilzomib + Pomalidomide + Dexamethasone